Company Description
vVARDIS has created a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth.
Our proprietary peptide-enabled technology platform, Curodont®, delivers an early therapeutic solution for tooth decay, the world’s most prevalent non-communicable disease, addressing a massive global healthcare need that has historically lacked effective early-intervention medical treatment options.
Our Curodont® platform includes our flagship Curodont® products—Curodont® Repair Fluoride Plus, which is currently sold in the United States and generates the vast majority of our revenues, and Curodont® Repair, which is currently sold in our other markets.
| Country | Switzerland |
| Founded | 2020 |
| Industry | Household & Personal Products |
| Sector | Consumer Staples |
| Employees | 153 |
| CEO | Haley Abivardi & Goly Abivardi |
Contact Details
Address: Gubelstrasse 24 Zug, 6300 Switzerland | |
| Phone | +41 78 258 4860 |
| Website | vvardis.com |
Stock Details
| Ticker Symbol | VVVV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1907709 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Haley Abivardi | Co-Chief Executive Officer, Co-Founder and Co-Chair |
| Goly Abivardi | Co-Chief Executive Officer, Co-Founder and Co-Chair |
| Thomas Rondot | Chief Financial Officer and Chief People Officer |
| Juergen Stark | Director |
| Clifford zur Nieden | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Sep 15, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 11, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 2, 2026 | DRS | [Cover] Draft Registration Statement |
| Oct 25, 2022 | D | Notice of Exempt Offering of Securities |